首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   54520篇
  免费   4935篇
  国内免费   3257篇
耳鼻咽喉   535篇
儿科学   544篇
妇产科学   644篇
基础医学   7046篇
口腔科学   1095篇
临床医学   6716篇
内科学   8380篇
皮肤病学   763篇
神经病学   2953篇
特种医学   2481篇
外国民族医学   37篇
外科学   6042篇
综合类   7713篇
现状与发展   7篇
一般理论   2篇
预防医学   3318篇
眼科学   1553篇
药学   5499篇
  43篇
中国医学   2670篇
肿瘤学   4671篇
  2024年   92篇
  2023年   682篇
  2022年   1341篇
  2021年   2861篇
  2020年   1909篇
  2019年   1805篇
  2018年   1952篇
  2017年   1660篇
  2016年   1787篇
  2015年   2585篇
  2014年   3211篇
  2013年   2899篇
  2012年   4617篇
  2011年   4716篇
  2010年   3010篇
  2009年   2462篇
  2008年   3186篇
  2007年   3084篇
  2006年   2836篇
  2005年   2581篇
  2004年   1863篇
  2003年   1707篇
  2002年   1491篇
  2001年   1209篇
  2000年   1228篇
  1999年   1167篇
  1998年   655篇
  1997年   696篇
  1996年   555篇
  1995年   455篇
  1994年   372篇
  1993年   265篇
  1992年   339篇
  1991年   257篇
  1990年   222篇
  1989年   191篇
  1988年   153篇
  1987年   135篇
  1986年   105篇
  1985年   93篇
  1984年   52篇
  1983年   51篇
  1982年   25篇
  1981年   24篇
  1980年   14篇
  1979年   24篇
  1978年   11篇
  1973年   11篇
  1971年   9篇
  1969年   10篇
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
991.
Manipulation under anesthesia (MUA) combined with intra-articular steroid injection (ISI) is preferred in management of the refractory frozen shoulder (FS). This study aimed to evaluate the effect of MUA with ISI or not on pain severity and function of the shoulder.Data on 141 patients receiving MUA with primary FS refractory to conservative treatments for at least 1 month were retrospectively obtained from medical records. We performed propensity score matching analysis between patients receiving MUA only and those receiving MUA plus ISI, and then conducted logistic regression analysis to identify the risk factors for the need to other treatments during 6-month follow-up.More improvement in terms of the SPADI pain scores and passive ROM at 2 weeks after first intervention remained in patients receiving MUA plus ISI after matching. The need to other treatments during 6-month follow-up occurred in 10.6% patients (n = 141). Logistic regression analysis revealed that a repeat MUA 1 week after first intervention was a protective factor (OR 0.042; 95% CI 0.011–0.162; P = .000) and duration of disease was the only one risk factor (OR 1.080; 95% CI 1.020–1.144; P = .008) for the need to other treatments during follow-up.ISI immediately following MUA provided additional benefits in rapid relief of pain and disability for patients with refractory FS. Pain and disability of the shoulder may be rapidly alleviated by an earlier MUA from the onset of the symptoms and a repeat MUA 1 week after first intervention.  相似文献   
992.
993.
Acupuncture was proven beneficial in treating allergic inflammation. We aimed to explore the regulation underlying the effects of acupuncture on Feishu, an acupoint most commonly used in the acupuncture therapy for respiratory diseases, with respect to the system of sympathetic nerve neurotransmitter acetylcholine (Ach). Male Wistar rats were randomly grouping. No treatment was taken in the normal group. Allergic asthma was induced using ovalbumin on the model, Feishu acupuncture, and sham acupuncture groups; then control or acupuncture treatment lasting for 3 weeks was performed. Bronchoalveolar lavage fluid (BALF) from the four groups was examined. And pulmonary tissues were subjected to histological analysis with H&E staining; besides, immunofluorescent staining, quantitative PCR, and western blot were used to detect synthetase (ChAT) and Ach hydrolase (AchE), and its muscarinic receptors (mAchRs) M1-M3. There was inflammatory infiltration in the lung upon allergic asthma, which was alleviated by the Feishu acupuncture. The eosinophilic granulocytes, neutrophils, and lymphocytes in BALF from the Feishu acupuncture group were all significantly decreased compared with those of the model and sham acupuncture groups. The specific acupuncture on Feishu upon allergic asthma put down the pulmonary expression of ChAT, repaired at the level of gene expression the pulmonary expression of mAchR M1, and restored the pulmonary expression of mAchR M2 (especially in the bronchiolar epithelium) which has a role in inhibiting Ach release; while sham acupuncture had no effect. These results confirmed the therapeutic effects of Feishu acupuncture on allergic asthma, suggesting that the mechanisms may involve suppression of the Ach signal both from its synthesis and during its release.  相似文献   
994.
Mounting evidence has recently underscored the importance of DNA methylation in normal brain functions. DNA methylation machineries are responsible for dynamic regulation of methylation patterns in discrete brain regions. In addition to methylation of cytosines in genomic DNA (5-methylcytosine; 5mC), other forms of modified cytosines, such as 5-hydroxymethylcytosine, 5-formylcytosine, and 5-carboxylcytosine, can potentially act as epigenetic marks that regulate gene expression. Importantly, epigenetic modifications require cognate binding proteins to read and translate information into gene expression regulation. Abnormal or incorrect interpretation of DNA methylation patterns can cause devastating consequences, including mental illnesses and neurological disorders. Although DNA methylation was generally considered to be a stable epigenetic mark in post-mitotic cells, recent studies have revealed dynamic DNA modifications in neurons. Such reversibility of 5mC sheds light on potential mechanisms underlying some neurological disorders and suggests a new route to correct aberrant methylation patterns associated with these disorders.  相似文献   
995.
996.
In this study, we investigated the effect of bufalin on the human ether‐à‐go‐go‐related gene (hERG) K+ channels using the perforated patch recording technique. We measured a half‐maximal inhibitory concentration (IC50) of 24.83 μM and maximal inhibitory effect of 39.45 ± 1.14% with bufalin. These findings suggest that bufalin is a potent hERG K+ channel blocker and may provide a new way for understanding Chan Su‐induced arrhythmia.  相似文献   
997.
998.
Fingolimod (FTY720) is an orally available sphingosine‐1‐phosphate (S1P) receptor modulator reducing relapse frequency in patients with relapsing–remitting multiple sclerosis (RRMS). In addition to immunosuppression, neuronal protection by FTY720 has also been suggested, but remains controversial. Axial and radial diffusivities derived from in vivo diffusion tensor imaging (DTI) were employed as noninvasive biomarkers of axonal injury and demyelination to assess axonal protection by FTY720 in experimental autoimmune encephalomyelitis (EAE) mice. EAE was induced through active immunization of C57BL/6 mice using myelin oligodendrocyte glycoprotein peptide 35–55 (MOG35–55). We evaluated both the prophylactic and therapeutic treatment effect of FTY720 at doses of 3 and 10 mg/kg on EAE mice by daily clinical scoring and end‐point in vivo DTI. Prophylactic administration of FTY720 suppressed the disease onset and prevented axon and myelin damage when compared with EAE mice without treatment. Therapeutic treatment by FTY720 did not prevent EAE onset, but reduced disease severity, improving axial and radial diffusivity towards the control values without statistical significance. Consistent with previous findings, in vivo DTI‐derived axial and radial diffusivity correlated with clinical scores in EAE mice. The results support the use of in vivo DTI as an effective outcome measure for preclinical drug development. Copyright © 2013 John Wiley & Sons, Ltd.  相似文献   
999.
李秀娟  黄从新  丁家望  杨俊  吴辉  李莉  李松  李稳慧  姜玉蓉 《重庆医学》2012,41(20):2062-2063,2067
目的探讨猪心肌梗死(MI)后梗死边缘区快速延迟整流K+通道KCNH2和KCNE2基因表达水平的改变及意义。方法通过结扎猪左前降支远端1/3~1/2处2h建立急性心肌梗死(AMI)模型,手术后存活猪进入MI组,术后24h取左心室梗死边缘区内层(Endo)、中层(Mid)和外层(Epi)心肌,应用半定量RT-PCR方法检测KCNH2和KCNE2mRNA含量。同时,设立相应的假手术组(SH组),SH组取与MI组对应区域的心肌组织。结果 KCNH2和KCNE2基因的表达在SH组左心室En-do、Mid和Epi心肌间没有差异,与SH组比较,AMI后梗死边缘区3层心肌KCNH2mRNA表达均明显下降(P<0.05),而且3层心肌间的基因表达呈不均一性(P<0.05),KCNE2mRNA表达量差异无统计学意义(P>0.05)。结论 AMI后梗死边缘区3层心肌KCNH2基因表达的不均一性下调,可能在MI后早期室性心律失常的发生中起重要作用。  相似文献   
1000.
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号